Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism (dadpgm)
Perioperative Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Yulong Song
- Phone Number: 86-13519185656
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 40 and 60
- Selective epigastrium surgery
- In
Exclusion Criteria:
- American Society of Anesthesiology (ASA) Physical Status>3
- Duration of operation >3 hours
- Hypovolemia,sinus bradycardia,atrioventricular block,severe hepatic and renal dysfunction,severe cardiac insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dexmedetomidine
Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes, the speed in maintenance phase is 0.4μg/Kg.h
|
During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h
until 40 minutes before the end of surgery
Other Names:
|
|
Placebo Comparator: placebo
Patients in group P will be given normal saline during anesthesia induction and maintenance phase
|
During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sedation level
Time Frame: from 5 minutes before medication to 10 minutes after Dexmedetomidine discontinuance,length of time frame is about 2 hours
|
Ramsay score and BIS will be recorded before medication,5 min after medication, medication ending, 5 and 10 min after medication
|
from 5 minutes before medication to 10 minutes after Dexmedetomidine discontinuance,length of time frame is about 2 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
recorded at before medication,5 min after medication, medication ending, 5 and 10 min after medication, before intubation, after intubation, after skin incision,60 minutes after skin incision, after extubation,first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
Mean arterial pressure
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
10 min after medication, before intubation, after intubation, after skin incision,60 minutes after skin incision, after extubation,first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
blood glucose measured by Biochemical test
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
it will be recorded immediately after the entrance to the operating room, before operation, 60 minutes after incision, after extubation, first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
cortisol measured by Biochemical test
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
it will be recorded immediately after the entrance to the operating room, before operation, 60 minutes after incision, after extubation, first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
insulin measured by Biochemical test
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
it will be recorded immediately after the entrance to the operating room, before operation, 60 minutes after incision, after extubation, first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
adrenaline measured by Biochemical test
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
it will be recorded immediately after the entrance to the operating room, before operation, 60 minutes after incision, after extubation, first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
|
noradrenaline measured by Biochemical test
Time Frame: participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
it will be recorded immediately after the entrance to the operating room, before operation, 60 minutes after incision, after extubation, first day after operation
|
participants will be followed from operation day to first postoperative day,an expected average of 2 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
Other Study ID Numbers
- 20150618
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.